Q-omics provides the consensus-scored NPIPA3 profile across patient tissues and cancer cell-line models. NPIPA3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NPIPA3 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, NPIPA3 RNA expression shows 10,671 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, COAD, and THYM as cancer lineages where NPIPA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPA3 survival associations across molecular data types. NPIPA3 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPA3 RNA expression–survival associations across cancer types. High NPIPA3 expression shows unfavorable associations in LUAD, OV and KIRP, but favorable associations in PCPG, UCEC and STAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for NPIPA3 RNA expression.
This table summarizes NPIPA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPA3 shows lower tumor expression in BRCA, LUAD and THCA and higher tumor expression in COAD, KIRC and LIHC. The COAD box plot shows higher NPIPA3 RNA expression in tumor versus normal tissue (log2 FC = +0.326, t-test p < 0.001).
This table shows molecular features associated with NPIPA3 in patient tissues and cancer cell lines. In patient samples, NPIPA3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPIPA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
